Jia Qian-tao, Xu Li-hui, Zha Qing-bing, Li Feng-yao, He Xian-hui, Zeng Yao-ying
Institute of Tissue Transplantation and Immunology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007 Feb;23(2):97-101.
To optimize expression condition of HLA-A0203 heavy chain ectodomain fused with a BirA substrate peptide (BSP) (HLA-A0203-BSP) for E.coli BL21(DE3) transformant and to prepare a functional HLA-A*0203 tetramer loaded with an antigenic peptide derived from EBNA3(596-604) of Epstein-Barr virus (EBV).
The temperature, IPTG concentration and inductive duration of HLA-A0203-BSP fusion protein expressed for E.coli BL21(DE3) transformant were optimized. SDS-PAGE and Western blot analyses were employed to detect the expressed fusion protein. The monomer of soluble HLA-A0203-peptide was generated from the fusion protein by in vitro refolding of washed inclusion bodies in the presence of beta2-microglobulin (beta2m) and HLA-A*0203 restricted EBV EBNA3(596-604) peptide (SVRDRLARL, SVR). Refolded and purified monomer was then biotinylated with BirA. Following the purification of the obtained biotinylated monomer, the tetramer was formed by incubation with streptavidin-PE at a ratio of 4:1. Flow cytometry (FCM) analysis was performed to determine its binding activity with specific cytotoxic T lymphocytes (CTL).
SDS-PAGE and Western blot showed that the optimized expression condition was overnight induction at 37 degrees C with 0.4 mmol/L IPTG. The expressed protein of about 34 kDa in the form of inclusion bodies accumulated up to about 30% of total bacterial protein under the optimized expression condition. The monomer of soluble HLA-A0203/SVR was successfully generated and purified. Non-reducing SDS-PAGE analysis showed that the biotinylation was above 85%. HLA-A0203/SVR tetramer was constructed by mixing the monomer with streptavidin-PE at a ratio of 4:1. FCM analysis indicated that this tetramer could bind specific CTL from HLA-A2+ donors.
HLA-A0203-BSP fusion protein was overexpressed in E.coli under the optimized condition. The tetramers of HLA-A0203/SVR were prepared from this fusion protein and it possessed binding activity with specific CTL, which provided a powerful tool for direct visualization and quantification of specific CTL from HLA-A*0203 donors.
优化HLA-A0203重链胞外区与BirA底物肽(BSP)融合蛋白(HLA-A0203-BSP)在大肠杆菌BL21(DE3)转化子中的表达条件,并制备负载爱泼斯坦-巴尔病毒(EBV)EBNA3(596 - 604)抗原肽的功能性HLA-A*0203四聚体。
对大肠杆菌BL21(DE3)转化子表达HLA-A0203-BSP融合蛋白的温度、IPTG浓度和诱导时间进行优化。采用SDS-PAGE和Western blot分析检测表达的融合蛋白。在β2-微球蛋白(β2m)和HLA-A0203限制性EBV EBNA3(596 - 604)肽(SVRDRLARL,SVR)存在的情况下,通过洗涤后的包涵体体外重折叠从融合蛋白中产生可溶性HLA-A*0203-肽单体。然后用BirA对重折叠并纯化的单体进行生物素化。在纯化得到的生物素化单体后,与链霉亲和素-PE按4:1的比例孵育形成四聚体。进行流式细胞术(FCM)分析以确定其与特异性细胞毒性T淋巴细胞(CTL)的结合活性。
SDS-PAGE和Western blot显示,优化后的表达条件为在37℃用0.4 mmol/L IPTG过夜诱导。在优化的表达条件下,以包涵体形式表达的约34 kDa蛋白积累量高达细菌总蛋白的约30%。成功产生并纯化了可溶性HLA-A0203/SVR单体。非还原SDS-PAGE分析表明生物素化率高于85%。通过将单体与链霉亲和素-PE按4:1的比例混合构建了HLA-A0203/SVR四聚体。FCM分析表明该四聚体可与HLA-A2+供体的特异性CTL结合。
在优化条件下,HLA-A0203-BSP融合蛋白在大肠杆菌中过表达。由该融合蛋白制备了HLA-A0203/SVR四聚体,其具有与特异性CTL的结合活性,为直接可视化和定量来自HLA-A*0203供体的特异性CTL提供了有力工具。